The marketing analysis of anti-gout medicines presented at the pharmaceutical market of Ukraine

Authors

DOI:

https://doi.org/10.24959/nphj.20.30

Keywords:

gout, anti-gout medicines, pharmaceutical market, assortment

Abstract

Gout is one of the most common forms of joint inflammation. From year to year the number of patients in the world is increasing. Despite the effective methods of treatment, gout is not always diagnosed on time and the treatment of patients starts late. A very important issue in the pharmacotherapy of patients with this nosology is to provide them with the sufficient number of effective, safe and affordable medicines presented at the pharmaceutical market of Ukraine.
Aim. To conduct the marketing assortment analysis of anti-gout medicines (AGM) presented at the local pharmaceutical market, its features and development trends.
Materials and methods. In the study, data of the State Register of Medicines of Ukraine, Compendium – medicines and scientific articles of professional publications were used. The main research methods were systematic, comparative, marketing analysis of drug market structure, monitoring and graphical method.
Results and discussion. It has been determined that the Ukrainian market of AGM is formed mainly by foreign manufactures (55 %), has 9 trade names of medicines, 9 companies-manufactures from 6 countries of the world. Medicines of the study group are presented at the pharmaceutical market only in tablet form. It has been found that the allopurinol group medicines are less expensive, while imported medicines of the febuxostat group are of the maximum cost. Medicines that do not affect the metabolism of uric acid are presented by only one imported drug which has no local analog, and it significantly limits the consumers’ choice of available medicines for the treatment of gout.
Conclusions. The marketing analysis of the assortment of AGM presented at the pharmaceutical market of Ukraine as of March 2020 has been conducted. The low level of the physical and economic availability of these medicines for the population of the country has been revealed.

Author Biographies

V. P. Khodakivska, Zhytomyr Basic professional College of Pharmacy

candidate of pharmaceutical sciences, lecturer of higher qualification category

N. M. Senkiv, Zhytomyr Basic professional College of Pharmacy

lecturer of the first qualification category

References

Denisov, I. S., Eliseev, M. S., Barskova, V. S. (2013). Nauch.–prakt. revmatol., 51 (5), 569–573.

Kuo, C. F., Grainge, M. J., Zhang, W., Doherty, M. (2015). Global epidemiology of gout: prevalence, incidence and risk factors. Nat. Rev. Rheumatol., 11 (11), 649–662. doi: 10.1038/nrrheum. 2015.

Paliienko, I. A., Karmazina, O. M. (2015). Ukr. revm. zhurn., 4 (62), 672.

Neogi, T., Jansen, T., Dalbeth, N. et al. (2015). Gout Classification Criteria. An American College of Rheumatology. Collaborative Initiative Arthritis & Rheumatology, 67 (10), 2557–2568.

Smiian, S. I. (2010). Hostri ta nevidkladni stany u praktytsi likaria, 4, 23.

Shuba, N. M. (2013). Ukr. revm. zhurn., 2 (52), 14-21.

Korzh, A. N. (2015). Skhidnoievropeiskyi zhurn. vnutrishnoi ta simeinoi medytsyny, 1, 40–47.

Derzhavnyi reiestr likarskykh zasobiv Ukrainy. (n. d.). Available at: http://www.drlz.com.ua/.

Baza standartiv medychnoi dopomohy v Ukraini. (n. d.). Available at: http://www.moz.gov.ua/ua/portal/register_standardsofmedicalaid.

Kompendyum – lekarstvennыe preparaty. (n. d.). Available at: https://compendium. com.ua/.

Kotvitskaia, A. A., Karlo, V. V. (2013). Problemy sotsialnoi hihieny, zdravookhraneniia i istorii medytsyny, 3, 50–53.

Morion. Prohrammnyi kompleks “APTEKA”. (n. d.). Available at: https://pharmbase.com.ua/ru/.

Downloads

Published

2020-09-24

Issue

No. 2(100) (2020)

Section

Organization and Economy of Pharmacy

License

Copyright (c) 2020 National University of Pharmacy

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).